Paper25634992
Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.
Alm RA and 2 others. J Antimicrob Chemother, 2015. Cited by 167 papers, by iCite.
Cite this record
ConductScience Library. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. Papers, record 25634992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25634992
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Azabicyclo Compounds | Major topic |
| Aztreonam | Major topic |
| Escherichia coli | Major topic |
| Penicillin-Binding Proteins | Major topic |
| beta-Lactam Resistance | Major topic |
| beta-Lactamases | Major topic |
| Computational Biology | |
| Escherichia coli Infections | |
| Genome, Bacterial | |
| Humans | |
| Microbial Sensitivity Tests | |
| Mutagenesis, Insertional | |
| Sequence Analysis, DNA |
Source PubMed
Cited by116
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 167 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42932391 | L-Histidine resensitizes multidrug-resistant bacteria to carbapenems by inhibiting New Delhi metallo-β-lactamase activity. | PLoS Pathog | 2026 | https://conductscience.org/library/papers/42932391 | PubMed |
| 42747332 | Escherichia coli with penicillin-binding protein 3 insertions: implications for newer β-lactam/β-lactamase inhibitor combinations. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/42747332 | PubMed |
| 42650674 | Clinical Emergence and Genomic Characterization of Aztreonam-Avibactam-Resistant Escherichia coli ST410 Isolates in China. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42650674 | PubMed |
| 42593110 | Outbreak of aztreonam-avibactam-resistant NDM-5-producing Escherichia coli isolates in a hospital of Paris. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/42593110 | PubMed |
| 42549896 | In vitro susceptibility testing of aztreonam-avibactam against predominantly NDM-producing Enterobacterales in Peru. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/42549896 | PubMed |
| 42379811 | In vitro activity of aztreonam-avibactam and comparators against Enterobacterales isolated from bloodstream infections: ATLAS/ surveillance, 2021-2022. | Microbiol Spectr | 2026 | https://conductscience.org/library/papers/42379811 | PubMed |
| 42267316 | Carbapenemases: epidemiology, detection and management in a changing global landscape. | JAC Antimicrob Resist | 2026 | https://conductscience.org/library/papers/42267316 | PubMed |
| 42103067 | Emergence of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae with Penicillin-Binding Protein 3 Insertions, Taiwan, 2021. | Emerg Infect Dis | 2026 | https://conductscience.org/library/papers/42103067 | PubMed |
| 42041376 | Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42041376 | PubMed |
| 41971938 | Successful treatment of carbapenem-resistant Acinetobacter baumannii and Enterobacterales coinfection with sulbactam-durlobactam combined with aztreonam: a case report. | AME Case Rep | 2026 | https://conductscience.org/library/papers/41971938 | PubMed |
| 41940810 | Case Commentary: When one target is not enough-PBP3 insertions and target redundancy in Escherichia coli. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/41940810 | PubMed |
| 41870042 | Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant Escherichia coli. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/41870042 | PubMed |
| 41606461 | Genome-wide screening of antibiotic survival genes in Escherichia coli MG1655. | BMC Microbiol | 2026 | https://conductscience.org/library/papers/41606461 | PubMed |
| 41577890 | Aztreonam plus ceftazidime/avibactam broth disk elution test: failure to detect Escherichia coli with PBP-3 insertions. | Eur J Clin Microbiol Infect Dis | 2026 | https://conductscience.org/library/papers/41577890 | PubMed |
| 41334908 | APC24-7, a covalent combination of boronic acid and chelator moieties, restores β-lactam efficiency against metallo-β-lactamase-producers. | mSphere | 2025 | https://conductscience.org/library/papers/41334908 | PubMed |
| 41258612 | Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms. | Drugs | 2026 | https://conductscience.org/library/papers/41258612 | PubMed |
| 41140275 | Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019. | J Antimicrob Chemother | 2025 | https://conductscience.org/library/papers/41140275 | PubMed |
| 41071106 | In vitro evolution of durlobactam resistance in NDM-producing Escherichia coli due to a single mutation in mrdA encoding penicillin-binding protein 2. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/41071106 | PubMed |
| 40756421 | In vivo evolution of ceftazidime-avibactam resistance in bla OXA-244-positive E. coli potentially linked to PBP3 insertion and mutations in acrB and PBP2. | JAC Antimicrob Resist | 2025 | https://conductscience.org/library/papers/40756421 | PubMed |
| 40711423 | Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/40711423 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25634992
GET https://conductscience.org/api/papers/v1/25634992/cited_by?page=2